Substance / Medication

Mazindol

Overview

Active Ingredient
mazindol
RxNorm CUI
6664

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

426 trials linked to this intervention

426
Total Trials
122
Recruiting
109
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.
Lucchetta Rosa Camila, Riveros Bruno Salgado, Pontarolo Roberto et al. · Clinics (Sao Paulo) · 2017
PMID: 28591345Meta-AnalysisFull text (PMC)
Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects.
Arguelles-Tello Federico Alberto, Kammar-García Ashuin, Trejo-Jasso Cristian Adolfo et al. · Int J Clin Pharmacol Ther · 2022
PMID: 35770520RCTFull text (PMC)
Efficacy and safety of the metformin-mazindol anorectic combination in rat.
Argüelles-Tello Federico, Roa-Coria José Eduardo, Zúñiga-Romero Ángel et al. · Acta Pharm · 2021
PMID: 33151165Observational
Validated method for determination of mazindol in human plasma by liquid chromatography/tandem mass spectrometry.
Kim Sung-Su, Lee Heon-Woo, Lee Kyung-Tae · J Chromatogr B Analyt Technol Biomed Life Sci · 2009
PMID: 19272843Observational
Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies.
Raffel David M, Chen Wei · Naunyn Schmiedebergs Arch Pharmacol · 2004
PMID: 15300361Observational
Assessment of mazindane, a pro-drug form of mazindol, in assays used to define cocaine treatment agents.
Houlihan William J, Kelly Lawrence · Eur J Pharmacol · 2003
PMID: 12504782Observational
Mazindol administration improved hyperphagia after surgery for craniopharyngioma--case report.
Sadatomo T, Sakoda K, Yamanaka M et al. · Neurol Med Chir (Tokyo) · 2001
PMID: 11381681Case Report
Delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol: a case report.
Hagiwara M, Tsuchida A, Hyakkoku M et al. · Jpn Circ J · 2000
PMID: 10732856Case Report
Changes in Body Weight in Severely Obese Patients Treated with the Anorexiant Mazindol.
Tanaka Yoshimitsu, Maeda Norikazu, Koseki Masahiro et al. · J Clin Med · 2024
PMID: 38610625OtherFull text (PMC)
Combined First Month Body Weight Loss and Development of Tolerance as Predictors of 6-Month Efficacy of Mazindol in Mild and Moderate Obese Subjects.
Huerta-Cruz Juan Carlos, Rocha-González Héctor Isaac, Kammar-García Ashuin et al. · J Clin Med · 2022
PMID: 35683598OtherFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mazindol (substance)
SNOMED CT
387232005
UMLS CUI
C0024977
RxNorm CUI
6664

Clinical Data

This intervention maps to 11 entities in the Ltrl knowledge graph.

3
Conditions
3
Biomarkers
3
Specialists
0
Symptoms
426
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.